HER2 gene, the well-known driver of breast cancer, also contributes to around 3 percent of lung cancers, representing about 6,500 patients per year.
But while drugs like trastuzumab and lapatinib have proven effective in silencing the action of HER2 in breast cancer, there are currently no approved HER2-targeted therapies for the treatment of lung cancer.
Now, a University of Colorado Cancer Center study presented at the 30th annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer ...
HER2 gene, the well-known driver of breast cancer, also contributes to around 3 percent of lung cancers, representing about 6,500 patients per year.
But while drugs like trastuzumab and lapatinib have proven effective in silencing the action of HER2 in breast cancer, there are currently no approved HER2-targeted therapies for the treatment of lung cancer.
Now, a University of Colorado Cancer Center study presented at the 30th annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer ...